Compare TCPC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | BCYC |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 360.7M |
| IPO Year | 2006 | 2019 |
| Metric | TCPC | BCYC |
|---|---|---|
| Price | $4.22 | $4.68 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $3.50 | ★ $13.90 |
| AVG Volume (30 Days) | ★ 1.0M | 371.9K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 18.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $4.24 |
| 52 Week High | $8.05 | $9.55 |
| Indicator | TCPC | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 41.03 |
| Support Level | $3.43 | $4.24 |
| Resistance Level | $4.49 | $5.41 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 63.95 | 2.00 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.